Welcome to our dedicated page for Amedisys SEC filings (Ticker: AMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amedisys, Inc. (AMED) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents, along with AI-powered summaries to help interpret complex disclosures. As a former Nasdaq-listed healthcare at home company, Amedisys filed a range of reports that describe its home health, hospice and high acuity care businesses, financial performance, risk factors and corporate transactions.
Investors reviewing Amedisys filings will find annual reports on Form 10-K and quarterly reports on Form 10-Q that detail net service revenue, operating expenses, net income, cash flows, balance sheet data and non-GAAP measures such as adjusted EBITDA and adjusted net income. These filings also include discussions of reimbursement, regulatory risk, competition in the healthcare industry, and operational considerations such as staffing and referral relationships. Stock Titan’s AI tools can highlight key sections, summarize segment performance and explain the implications of accounting and non-GAAP adjustments.
Current Reports on Form 8-K are particularly important for understanding major events affecting Amedisys. For example, an August 14, 2025 Form 8-K describes the completion of the merger between Amedisys and a wholly owned subsidiary of UnitedHealth Group, under which Amedisys became a wholly owned subsidiary of UnitedHealth Group and Amedisys common stock was converted into the right to receive cash consideration. Related 8-K items discuss the termination of senior credit facilities, changes in control, board resignations and amendments to corporate governance documents.
The filings set also includes Form 25 notifications filed in August 2025 regarding the removal of Amedisys common stock from listing on the Nasdaq Stock Market and deregistration under Section 12(b) of the Exchange Act, as well as a Form 15 filed on August 25, 2025 to terminate registration under Section 12(g) and suspend reporting obligations under Sections 13 and 15(d). These documents mark Amedisys’ transition from a public company to a wholly owned subsidiary of UnitedHealth Group. On Stock Titan, users can use AI-generated overviews to quickly understand these changes, while still having access to the full text of each SEC filing for detailed review.
Amedisys, Inc. submitted a post-effective amendment to deregister any and all shares of its common stock that remain registered but unsold or otherwise unissued under multiple previously filed S-8 registration statements. The filing lists the specific S-8 files and original share amounts for plans including employee stock purchase and omnibus incentive plans.
The notice clarifies that the listed share counts do not account for interim corporate actions such as stock splits.
Amedisys Inc. Schedule 13G shows Pentwater Capital Management LP and Matthew Halbower disclose beneficial ownership of 1,715,084 shares of Amedisys common stock, representing 5.2% of the class based on 32,819,638 shares outstanding as of April 25, 2025. The shares are held directly by the Pentwater Funds with Pentwater acting as investment manager; Mr. Halbower is disclosed as the sole shareholder of the general partner of the manager. The filing states the position is held in the ordinary course of business and not to influence control. Signatures dated 08/14/2025 accompany a joint filing agreement.
Amedisys director Molly Joel Coye reported the disposition of all her Amedisys (AMED) common shares due to the closing of a merger on 08/14/2025. UnitedHealth Group completed its previously announced acquisition under the Merger Agreement dated 06/26/2023 (as modified by a 12/26/2024 waiver), causing each outstanding Amedisys share to convert into the right to receive $101 per share in cash. The Form 4 shows a disposition of 8,818 shares (including conversion of 1,690 time-based RSUs) and reports 0 shares beneficially owned by the reporting person following the transaction.
Amedisys Inc. (AMED) was acquired by UnitedHealth Group and ceased to be an independent public company on 08/14/2025. Under the Merger Agreement, Aurora Holdings Merger Sub Inc. merged with and into Amedisys, leaving Amedisys as a wholly owned subsidiary of UnitedHealth Group. At the Effective Time each outstanding Amedisys common share converted into the right to receive $101.00 per share in cash, less any applicable withholding tax. Reporting person Julie D. Klapstein, a director, reported a disposition of 16,031 shares on 08/14/2025, resulting in zero beneficial ownership following the transaction. The reported disposition includes 1,690 time-based RSUs that were cancelled and converted into the same per-share cash consideration.
Amedisys was acquired by UnitedHealth Group on August 14, 2025, and each outstanding Amedisys share converted into $101.00 in cash at the merger effective time. The reporting person, Chief Strategy Officer Nick Muscato, had previously held 32,620 Amedisys shares which converted into cash, and certain restricted and performance-based awards converted into UnitedHealth Group RSUs using the merger's Equity Award Exchange Ratio. The filing shows 3,468 performance-based RSUs were earned at 127.23% of target for 2023 Adjusted EBITDA and converted into time-based UnitedHealth Group RSUs that vest on December 31, 2025. Multiple stock options and RSUs were converted or settled under the merger terms; some options remain fully vested while others retain scheduled vesting.
Teresa L. Kline, a director of Amedisys, reported the disposition of her common stock following the company's merger with UnitedHealth Group. On 08/14/2025 9,818 shares were disposed of and her post-transaction beneficial ownership is 0 shares. The filing explains that UnitedHealth completed the acquisition under a merger agreement under which each Amedisys share (other than excluded shares) converted into the right to receive $101.00 per share in cash. The filing also states that 1,690 time-based RSUs outstanding at the Effective Time were cancelled and converted into the same per-share cash consideration.
Amedisys was acquired by UnitedHealth Group on August 14, 2025, and each outstanding Amedisys share converted into the right to receive $101.00 per share in cash. The filing by Richard M. Ashworth (President and CEO and director) shows multiple equity awards and holdings converted or settled under the merger terms: outstanding common shares were disposed of or converted, performance-based restricted stock units (PSUs) and restricted stock units (RSUs) were converted into UnitedHealth Group RSUs using an equity award exchange ratio, and stock options were converted into UnitedHealth Group options with adjusted exercise prices. Specific amounts reported include the cash conversion of common stock holdings and conversions of 62,641 PSUs (time-based UnitedHealth RSUs vesting April 12, 2026) and 39,850 PSUs (vesting December 31, 2025), plus conversion of 22,474 option shares (11,237 vested; 11,237 vesting Feb 20, 2026). The filing documents the mechanics of the conversion and preserves original vesting and settlement terms where specified.
Amedisys director Samuels Ivanetta Davis reported a disposition of all her Amedisys (AMED) common stock on 08/14/2025 in connection with the company's merger into UnitedHealth Group. At the Effective Time of the merger each outstanding Amedisys share converted into the right to receive $101 per share in cash. The Form 4 shows a disposition of 7,600 common shares, and separately discloses that 1,690 time-based RSUs were cancelled and converted into the same per-share cash consideration. Following the reported transaction the reporting person beneficially owned 0 shares. The filing is an exchange of equity for the specified cash merger consideration, not an open-market trade.
Amedisys completed a cash sale to UnitedHealth Group, effective August 14, 2025. Each outstanding share of Amedisys common stock was converted into the right to receive $101.00 per share in cash, less applicable withholding. At the Effective Time Amedisys became an indirect, wholly owned subsidiary of UnitedHealth Group.
The company terminated its senior secured credit facilities and paid an aggregate of $399,191,391.35 to satisfy outstanding obligations. Amedisys notified Nasdaq to suspend trading, withdraw its listing and file Form 25, and intends to file Form 15 to deregister and suspend reporting. Outstanding equity awards generally converted into UnitedHealth-denominated awards using an exchange ratio tied to the cash consideration and UnitedHealth stock trading levels; director RSU awards were canceled for cash equal to the per-share consideration. Several directors resigned as required by the merger agreement. Financial and transaction documents and counsel are noted in the filing.
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of 1,769,479.30 shares of Amedisys common stock, representing 5.4% of the class. The cover information shows shared voting power of 1,769,412.30 and shared dispositive power of 1,769,477.30, with no sole voting or dispositive power listed.
The filers include a joint filing agreement and certify the securities are held in the ordinary course of business and were not acquired to change or influence control. Reporting classifications include HC, CO, BD, OO, IA, reflecting parent-company and broker/adviser roles.